

# Keyword Index

- [18-F] Florbetaben . . . . . T228
- [18-F] Fluortriopride . . . . . M254
- [18F]ASEM . . . . . M7
- [18F]-FEPPA . . . . . 32.2
- 1H-MRS . . . . . 60.3, M165
- 22Q11 . . . . . 19.4
- 22q11.2 CNV . . . . . T196, T203
- 5C-CPT . . . . . T198
- 5CSRTT . . . . . M146
- 5-Ht1B . . . . . W65
- 5-Ht2A Receptor . . . . . W27, W244
- 5HT2A receptors . . . . . T170, W46
- 7-DHC . . . . . W51
- ABCD . . . . . 28.3
- Abstinence . . . . . 14, M229, M245, W229
- Abuse . . . . . W234
- Abuse Liability . . . . . M220
- Abuse Potential . . . . . T166
- Acculturation Stress . . . . . W276
- Accumbens . . . . . 14.2
- Acetylcholine . . . . . 9.1, T217, W45
- Acetylcholinesterase Inhibitors . . . . . W47
- Acoustic Startle Response . . . . . T215
- Actigraphy . . . . . 2.1, 21.4
- Action-Outcome Associations . . . . . W178
- Acute Effects . . . . . M252
- Acute Stress . . . . . 9.3, 30.4, 53, M105, T5, T7, T15,  
W21, W120, W121, W130,  
W144, W272
- Adaptive Deep Brain Stimulation . . . . . 18.3
- Addiction . . . . . 12, 12.2, 20.2, 20.4, M140, M272, T49,  
T238, T240, T244, T264, T279, W225,  
W231, W249, W260, W262,  
W267, W280
- Addiction Circuitry . . . . . M236, M263, W278
- Add-On Treatment . . . . . 44.1
- Adenosine A2A Receptor . . . . . M66
- Adiponectin . . . . . 16.4
- Adolescence . . . . . 6, 6.2, 6.3, 6.4, 11, 11.1, 23.1,  
28.2, 28.3, 29.3, 40.1, 40.2, 40.3, 40.4,  
48.1, 48.3, M33, M34, M35, M38,  
M48, M61, M227, M230, M267, T20,  
T81, T93, W35, W38, W40, W58
- Adolescent . . . . . 27.2, 28, T86
- Adolescent Academic Performance . . . . . W271
- Adolescent Alcohol . . . . . M233, W247
- Adolescent Anxiety . . . . . M26, M36, M143
- Adolescent Binge Drinking . . . . . T48
- Adolescent Brain and Cognitive Development . . . . . 6.4
- Adolescent Brain and Cognitive Development  
Study . . . . . 28.1, 28.3
- Adolescent Depression . . . . . 11.2, M36, M37, M40,  
M106, T88, T137, W33,  
W90, W123, W147
- Adolescent Development . . . . . 6.1, 23.3, 48.4, M168, T43
- Adolescent Stress . . . . . M268
- Adolescents . . . . . 5.2, 40, M49, T95
- Adult Hippocampal Neurogenesis . . . . . M40, M116, M120,  
T174
- Adult Onset . . . . . T204
- Advance Care Planning . . . . . T168
- Adverse Childhood Experiences . . . . . T13
- Adversity . . . . . 29, 29.3
- Advocacy . . . . . 62
- Aerobic Exercise . . . . . M267
- Affect of Adverse Events on Efficacy . . . . . M210
- Affect of Adverse Events on Functioning . . . . . M210
- Affective Components of Pain . . . . . 43, 43.1
- Affective Disorders . . . . . M102
- Age of Onset . . . . . M188
- Aggression . . . . . 38, 38.1, 38.2, 38.3, 38.4, M67,  
M153, M218, M246, T19, W66
- Aging . . . . . M4, M7, T1, T26, T56, T57, T176, W2, W110
- Aging and Dementia . . . . . M50, M53, T59
- Agonist Maintenance . . . . . 35.3
- Alcohol . . . . . 50.3, 54.1, M3, M246, M260,  
M268, T20, T55, T259, T277,  
T278, W248, W271
- Alcohol and Substance Use Disorders . . . . . 50.4, M241,  
M264, M271, T242,  
T258, W238, W243, W244,  
W245, W249, W272
- Alcohol Consumption . . . . . 59, T232, T262
- Alcohol Dependence . . . . . 54, 54.2, 54.3, M255, T52, T243,  
W237, W267
- Alcohol Drinking . . . . . 59.3, T255, T269, W248
- Alcohol Intake . . . . . 12.3, 59.2
- Alcohol Self-Administration . . . . . 59.4, M233, T249, W245
- Alcohol Sensitivity . . . . . T232, T280

- Alcohol Use Disorder . . . . . 59.3, M212, M230, T47,  
T249, T251, T266, T270,  
W242, W245, W260, W280
- Alcohol Withdrawal . . . . . M269, T265, W253
- Alcoholism . . . . . 59.1, M143, M144, M244, T254,  
T275, T281, W280
- Alcohol-Seeking Behavior . . . . . M66, T247
- ALKS 5461 . . . . . W119
- Allopregnanolone . . . . . M34
- Allostatic Load . . . . . 46
- Allosteric Modulator . . . . . T257
- Alpha Oscillation . . . . . 36.1, M47, W126
- Alpha-7 Nicotinic Acetylcholine Receptor . . . . . M7, T19
- ALS . . . . . T160
- Alternative Splicing . . . . . 59.1, T36
- Alzheimer's Disease . . . . . 46.2, M51, M54, T16, W1,  
W49, W165
- AMPA . . . . . M76, M128, W219
- AMPA Glutamate Receptors . . . . . T101
- AMPA Receptors . . . . . 37.3, W91, W219
- AMPA TARP Gamma8 . . . . . W91
- Amphetamine . . . . . T18, T237, W29, W206
- Amygdala . . . . . 29.1, 53.1, 53.4, 55.3, M10, M13, M65, M114,  
M134, T15, T22, T48, T72, T82,  
T125, T150, T194, T277, W7, W39,  
W52, W74, W96, W114, W123,  
W171, W235
- Amygdala-Hippocampal Differences . . . . . M172
- Amyloid . . . . . M5, W48
- Analgesia . . . . . M232, T124, W281
- Anandamide . . . . . 41.1, 41.3, T5
- Anatomical Connectivity . . . . . W32
- Anesthesia . . . . . T144
- Angiogenesis . . . . . M164
- Anhedonia . . . . . 17.3, M22, M251, T49, T122, W114, W133
- Animal Model . . . . . 8, 20.3, 29.1, 38, 38.2, 62, M247,  
T35, T84, T171, T222, T272, W78,  
W115, W154, W180, W246
- Animal Research . . . . . 62
- ANK3 . . . . . T23
- Ankryin-G . . . . . M177
- Anorexia Nervosa . . . . . T104, W54, W58, W59
- Anterior Cingulate . . . . . W203
- Anterior Cingulate Cortex . . . . . M146, M278, T93, T248
- Anterograde Tracer . . . . . M45
- Anthranilic Acid . . . . . T192, W176
- Antidepressant . . . . . 10.4, 49, 57.2, 57.3, M71, M98,  
M99, M100, M118, M124, M130,  
T75, T82, T111, T146, W24, W79,  
W107, W127, W129, W139, W147
- Antidepressant Agents . . . . . W118
- Antidepressant Response . . . . . W103
- Antidepressant Therapies . . . . . 30.4
- Antidepressant Treatment Practice . . . . . 57.4
- Antidepressant Trials . . . . . 10.1, W76
- Antipsychotic . . . . . 52.1, M217, T189, T209, W204
- Antipsychotic Induced Weight Gain . . . . . W210, W218
- Antipsychotic Medication . . . . . 47.4, M54
- Antipsychotic Response . . . . . M167
- Antipsychotic Treatment . . . . . 61.2, M200, T184, T214, W172
- Antipsychotic-Associated Obesity . . . . . W30
- Antipsychotic-Naïve First-Episode Schizophrenia . . . . . 52,  
52.2, 52.4, 58.3,  
M167, T45, T188
- Antipsychotic-Naive Schizophrenia . . . . . M179
- Antipsychotics . . . . . 7.4, M207, M212, T41, T184,  
W127, W187, W199
- Antisocial Personality Disorder . . . . . T180
- Anxiety . . . . . 4.3, 29.3, 30, 48.1, 55.3, M8, M10,  
M13, M73, M120, M137, M145, T2,  
T7, T14, T20, T49, T62, T63, T69,  
T72, T116, T121, T167, W7, W11,  
W24, W39, W48, W94, W115, W122
- Anxiety Circuitry . . . . . 4.2, 30.3, 55.4, M17, M23
- Anxiety Disorders . . . . . 41.2, T157, W15, W23
- Anxious Depression . . . . . T62
- APOE . . . . . T228
- App . . . . . 39
- Apparent Diffusion Coefficient . . . . . M156
- Appetitive Hormones . . . . . T246
- Approach/Avoidance . . . . . M127, M151, W131
- Aripiprazole . . . . . M199, W51, W189
- Aromatase . . . . . 44.2
- Artefact Removal . . . . . W256
- Arterial Spin Labeling . . . . . M150
- Artificial Learning . . . . . W271
- Aspirin . . . . . M216, T29
- Assessment . . . . . T206
- Associative Learning . . . . . W275
- ASSR . . . . . W192
- Astrocyte . . . . . 58.1, M100, W261
- Attachment . . . . . 29.1, W155
- Attention . . . . . M197, T4, T83, T93, T198
- Attention Deficit Hyperactivity Disorder (ADHD) . . . . . 11.3,  
M67, M142, M158, T9,  
T74, T108, W28, W55, W252
- Attentional Bias Modification . . . . . M57
- Atypical Antipsychotic Drug . . . . . W221
- Atypical Antipsychotics . . . . . T206, W212
- Auditory . . . . . 19.3, T199
- Auditory Cortex . . . . . 56.1

- Auditory Deficits in Schizophrenia . . . . . T205
- Auditory Hallucinations . . . . . 36.1, T42, T207, W191
- Auditory Processing . . . . . T40
- Auditory Short-Term Memory . . . . . T205
- Augmentation . . . . . 51.1
- Autism Spectrum Disorder . . . . . 1.3, 8, 22.1, 56.4, M39, M47, M92, M147, M148, M150, M158, M164, M204, M213, M215, T76, T83, T85, T86, T90, T92, T173, T203, W32, W37, W41, W42, W43, W180, W143, W150
- Autoimmune Encephalitis . . . . . W163
- Automated Facial Affect Recognition . . . . . 18.3
- Autonomic Nervous System . . . . . 22.3, W272
- Autophagosome . . . . . M203
- Autoradiography . . . . . T193
- Aversive Conditioning . . . . . T68
- Axon Guidance Molecule Genes . . . . . 6.1, W149
- Axons . . . . . M177
- Baby-Cry . . . . . M266
- Balb/C Mouse . . . . . W143
- Bariatric Surgery . . . . . M56, T164, W61
- Basal Ganglia . . . . . M273, T238
- Basolateral Amygdala . . . . . M145, M277, T273, W11, W154
- Bath Salts . . . . . W230
- Bayesian Inference . . . . . 12.2
- Bayesian Modeling . . . . . M151
- BDNF . . . . . 38.3, M131, M132, M217, M224, T39, T79, T146, T178, W156
- BDNF Delivery . . . . . T97
- BDNF Val66Met . . . . . W72
- Bed Nucleus Of The Stria Terminalis . . . . . 30.3, 55.2, 55.4
- Behavior . . . . . T30, T92
- Behavioral Analysis . . . . . T7
- Behavioral Disturbances . . . . . M54
- Behavioral Economics . . . . . M89
- Behavioral Inhibition . . . . . 37, W7
- Behavioral Pharmacology . . . . . M247, W236, W251
- Benzodiazepine . . . . . M239, W122, W258
- Benzodiazepine Diversion . . . . . W258
- Benzodiazepine Use Disorder . . . . . W258
- Beta-Amyloid Peptide 1-42 . . . . . T228
- Big Data . . . . . 7.2
- Binge Eating Disorder . . . . . M57, M62, T103, W55
- Bioenergetic . . . . . W213
- Bioinformatics . . . . . M99, T117, W215
- Biomarker . . . . . 1.3, 2, 2.4, 6, 7, 7.3, 7.4, 10, 10.4, 15, 47, 49.2, 52, 52.3, 56.2, 56.4, 57, 58.1, M9, M15, M111, M170, M172, T1, T27, T33, T169, T253, W23, W191, W144
- Biotype . . . . . M172, W211
- Bipolar . . . . . T221, W211
- Bipolar and Unipolar Depression . . . . . T133
- Bipolar Depression . . . . . M101, W81, W140
- Bipolar Disorder . . . . . 5, 5.1, 11.4, 21, 21.1, 33.3, 33.4, 60.1, M4, M70, M78, M81, M92, M102, M115, M119, M123, M190, M206, T23, T24, T25, T29, T78, T108, T112, T118, T119, T123, T135, T140, T150, T153, T202, T219, W78, W85, W96, W110, W111, W112, W227
- Bipolar I Depression . . . . . T75
- Bipolar I Disorder . . . . . 5.3, W190
- Blast . . . . . M157
- Blood . . . . . 52.3
- Blood Plasma Analyte . . . . . 13.1
- Blood Pressure . . . . . M153
- Blood-Brain Barrier . . . . . M178, W84
- BNST . . . . . 55.3, T72
- Bodies . . . . . T104
- Body Dysmorphic Disorder . . . . . T104
- Body Perception . . . . . W226
- Body Weight . . . . . W49, W118
- Bold Imaging . . . . . T64, T126, T187
- Borderline Personality Disorder . . . . . W170
- Botox . . . . . W79
- Brain . . . . . 44.2, W263
- Brain Based Markers for Depression . . . . . M126
- Brain Connectivity . . . . . 49.3, M112, T248
- Brain Development . . . . . 6.3, 11.4, 23.2, 23.3, 27.1, 28, 28.4, 29, 29.3, 55.3, M22, T91, T105, W39, W66, W243
- Brain Glucose Metabolism . . . . . T281
- Brain Imaging . . . . . 7, 10.2, 33.1, M44, M127, M259, W60
- Brain Networks . . . . . 7.2, 49.3
- Brain Stimulation . . . . . 36.1, M59, W37
- Brain Stress . . . . . T257
- Brain Structure . . . . . T30, T227
- Brain Transcription . . . . . 10.3, M236
- Brain Volume . . . . . M25, M257, T17
- Brain Wiring . . . . . T154
- Breast Cancer . . . . . W71
- Breast Cancer Chemotherapy . . . . . T167
- Brexanolone . . . . . W116
- Brexipiprazole . . . . . M208, M210, M211
- Bulimia Nervosa . . . . . T102, W56
- Buprenorphine . . . . . 35.1, M77, W94
- Buprenorphine-Naloxone . . . . . 35.2, 35.3, M225

CACNA1C . . . . .	W169	Choice . . . . .	T243, T276, W251
Calcium . . . . .	W169	Cholesterol Biosynthesis . . . . .	T278, W51, W88
Calcium Imaging . . . . .	W65, W75, W155, W262	Cholinergic Function . . . . .	W45
Calthrin Nanoparticles . . . . .	T97	Cholinergic System . . . . .	T252
cAMP Signalling . . . . .	T146	Chorioamnionitis . . . . .	22.4
Cancer . . . . .	32, 32.1, W3	Choroid Plexus . . . . .	20.1
Cancer Quality of Care . . . . .	T168	Chronic Food Restriction Stress . . . . .	W59
Cancer Survival . . . . .	T58	Chronic Pain . . . . .	25, W227
Cannabidiol . . . . .	M152	Chronic Pain Treatment . . . . .	25.3, 43, 43.2, T166
Cannabinoids . . . . .	T70, T199, W231, W234, W236	Chronic Social Defeat . . . . .	M126
Cannabis . . . . .	41.1, M201, T236, T268, W246, W264	Chronic Stress . . . . .	17.1, 30.4, 53, M24, M120, T15, T59, T148, T217, T273, W36, W84, W117, W121, W130, W144
Cannabis Dependence . . . . .	41.4	Cingulo-Opercular Network . . . . .	T13
Cannabis Use . . . . .	M141, M219, T43, T55, T274, W265	Circadian Function . . . . .	40.3
Cannabis Use Disorder . . . . .	41, M226, M282	Circadian Rhythm . . . . .	21, 21.4, 40, 40.1, 40.4, M221, T153, T210, T244, W96, W214
Cardiac Autonomic Tone . . . . .	T73	Circuit . . . . .	6.1, 24.1, 42.1
Cardiolipin . . . . .	M115	Circuit Mapping . . . . .	M182, M240
Cardiometabolic Risk . . . . .	W30	Circular RNA . . . . .	20, 20.3
Cardiovascular . . . . .	M87, M253	Circulating miRNA . . . . .	20.1
Care Coordination . . . . .	M225	CLARITY . . . . .	W185
Cariprazine . . . . .	T152, W81, W189	Clastrum . . . . .	W134
Catecholamine Depletion . . . . .	M58	Clinical High Risk . . . . .	13, 19.2, T197, W179, W182, W222
Cats/Foxes . . . . .	W166	Clinical High Risk for Psychosis . . . . .	M165, M201
Caudate . . . . .	M161, W34, W203	Clinical Outcome Prediction . . . . .	33.4
Causal Modeling . . . . .	M21	Clinical Trial . . . . .	2.4, 44, M79, M149, M175, M212, M255, T6, T40, T41, T159, T269
CB1 Receptor . . . . .	M277	Clinical Trial Rating Methods . . . . .	W139
CBT . . . . .	T3, W17	Clinician Reported Outcomes . . . . .	W76
Celecoxib . . . . .	M101, T135, T140	Clozapine . . . . .	M183, W221
Central Amygdala . . . . .	9.2, 14.4, 30.2	Clustering . . . . .	49.3, M243, T89, W260
Central Autonomic Network . . . . .	T73	CNS Antibody Delivery . . . . .	T96
Central Nucleus of the Amygdala . . . . .	55.2, 55.4	CNS Clinical Trials . . . . .	M51, T103
Cerebellum . . . . .	M264, T34, W150, W194	CNTNAP2 . . . . .	W42
Cerebral Blood Flow . . . . .	M150	Co-Abuse . . . . .	M260
Cerebrospinal Fluid . . . . .	13, 13.3, 20.1, T96	Cocaine . . . . .	37, 50.3, M270, T51, T53, T229, T230, T231, T261, T271, T279, T282, W261, W273, W279
C-Fos . . . . .	W279	Cocaine Addiction . . . . .	20.3, 37.2, 37.3, 50.2, M63, M247, M251, M253, M254, T248, T250, W229, W269
C-Fos-Expressing Ensembles . . . . .	50.1	Cocaine Seeking . . . . .	14, M229, M238, M277, W268, W274
Chemogenetics . . . . .	30.1, 37.2, M48, W62, W266	Cocaine Self-Administration . . . . .	M236, M237, M267, T273, W240
Chemokine . . . . .	58.3	Cognition . . . . .	2.4, 6, 19, 24.2, 24.4, 32.1, 32.3, 36.2, 42.2, 46.2, M79, M159, M168, M169, M206, T34, T39, T57, T163, T167, T191, T213, T223, T227, T256, W50,
Child Maltreatment . . . . .	M32		
Childhood . . . . .	T165		
Childhood Adversity . . . . .	29.4, W177		
Childhood Maltreatment . . . . .	29.1, T113		
Childhood Onset Bipolar Disorder . . . . .	T125		
Childhood Trauma . . . . .	29.4, M37, M42, M46, T28, T207, T274		
Childhood Urban-Rural Upbring . . . . .	M171, M184		
Childhood-Onset Schizophrenia . . . . .	M174		
Children . . . . .	11, 22, T10, T41		
Children and Adolescents . . . . .	28.1, 28.4, M67, T9, T14, W6, W26, W39		

W121, W141, W145, W182, W188,  
W202, W209, W220, W264

Cognitive Aging . . . . . M5

Cognitive Behavioral Therapy . . . . . M161, T87, T143,  
T218, W26

Cognitive Control . . . . . M117, M186, M192, M227,  
M245, T13, T83, T105, T106,  
T118, W201

Cognitive Control Network . . . . . T86

Cognitive Decline . . . . . M206, W3

Cognitive Deficits . . . . . 22.4, 52.2

Cognitive Enhancement . . . . . 31.1, M6, T182, W145, W184

Cognitive Flexibility . . . . . 59.4, W8

Cognitive Function . . . . . T272, W49

Cognitive Functioning . . . . . 31, M274, T182, W172

Cognitive Impairments . . . . . 36, M195

Cognitive Neuroscience . . . . . M40, M68

Cognitive Phenotypes . . . . . 26, T37, W74

Cognitive Reappraisal . . . . . W138, W170

Cognitive Remediation . . . . . M218, W173

Cognitive Symptoms . . . . . M170

Cognitive Training . . . . . 24.2, 36.3

Cognitive/Emotional Task Performance . . . . . M117, W13

Colony Stimulating Factor-1 . . . . . T148

Combat Veteran . . . . . 51.4, T64

Comparative Neuropsychopharmacology . . . . . M274

Comparative Studies . . . . . M181

Compulsive Behavior . . . . . 12.3, W18

Compulsive Models of Drug Use . . . . . T255

Compulsivity . . . . . T242, T243

Computational Modeling . . . . . 12, M245, T106, W63, W131

Computational Psychiatry . . . . . 33.1, 57.4, M259, T14,  
T63, W133, W137

Computerized Cognitive Training . . . . . T40

Concussion . . . . . T64

Conditioning . . . . . M273

Connectivity . . . . . 7.2, 27, M9, M19, M94,  
M124, T104, T130

Connectome . . . . . 23, W17

Consciousness . . . . . 3.3

Contingency Management . . . . . 14.4

Controlled Substance Scheduling . . . . . T166

Correlates . . . . . 61.1

Correlation Network . . . . . 13.1

Cortex . . . . . M201, W134

Cortical Circuit Function . . . . . M182, M186, M204

Cortical Excitability . . . . . T176

Cortical Excitation-Inhibition Balance . . . . . 19.2, M72, T23

Cortical Inhibition . . . . . M72

Cortical Neurons . . . . . M194

Cortical Plasticity . . . . . 60.1

Cortical Regulation . . . . . 37.2

Cortical Thickness . . . . . T163, T188, W205

Cortical Thinning . . . . . 13.2

Corticolimbic . . . . . M45

Corticosteroids . . . . . 22.1, W161

Corticosterone . . . . . T226, W143

Cortico-Striatal Circuit . . . . . W63

Corticostriatal Connectivity . . . . . 27.3, T154, W149

Corticostriatal Networks . . . . . T107

Corticotropin-Releasing Factor (CRF) . . . . . 9, 9.1, 9.2, M142,  
M246, T66, T257

Corticotropin-Releasing Hormone (CRH) . . . . . 9.3, W114

Cortisol . . . . . 22.3, 51.4, M21, M38, T132,  
W59, W100, W120

CPP . . . . . M248

Craving . . . . . 12.2, 12.4, M263, T251

C-Reactive Protein . . . . . M93

Creativity . . . . . M119

CRF-R1 . . . . . 9.2, M8

CRISPR/Cas9 . . . . . 45, M92, W86

Cross Generational Transmission . . . . . W265

CRP . . . . . M3

CSF Biomarkers . . . . . T96, T177, W41

Cue Reactivity . . . . . 50, 50.3, 50.4, M223, M238, M263, W67

Cue Reinstatement . . . . . M261, W278

Cue-Induced Craving . . . . . 50.2, M263, W246

Cuprizone Short-Term Exposure . . . . . W217

Cyclic AMP . . . . . T175

Cytochrome P450s . . . . . M69, W127

Cytokine . . . . . 8, 22, 54.3, M93, M129,  
M164, M204, M213, M215,  
M257, T84, T149, W84, W128

Cytoskeleton . . . . . M203

D1 Dopamine Receptors . . . . . 31, 31.1, 31.2, 31.3, T34, T234,  
W162, W193, W194

D2 Dopamine and 5HT2A Serotonin Antagonists . . . . . W46

D2 Receptor . . . . . M207, T53, W5, W134

dACC . . . . . 33.1, M26, T107

Dasotraline . . . . . T103

Data Fusion . . . . . W256

Data Quality . . . . . M175

D-Cycloserine . . . . . T87, W9, W26

De Novo Mutation . . . . . T76

Decision-Making . . . . . 31, M65, M89, M151, M259,  
T276, W235

Deep Brain Stimulation . . . . . 18.2, 18.3, M110, T128, W8

Default Brain Network . . . . . 38.4

Default Mode Network (DMN) . . . . . 12.4, 17.4, M56,  
M256, T89, T179



Deficit Syndrome. . . . .	T195	Dimensional . . . . .	M133
Delay Discounting . . . . .	M272, W62	Dimensions of Psychosis . . . . .	T207
Delirium . . . . .	W44	Dimethyltryptamine. . . . .	M2
Delta9-Tetrahydrocannabinol . . . . .	T43	Disorders of Glutamate . . . . .	16, W200
deltaFosB . . . . .	M107	Disparities. . . . .	T168
Dementia . . . . .	T160, T170, W47, W45, W48	Dissociation. . . . .	W140
Dementia-Related Psychosis . . . . .	W46	DLPFC . . . . .	M80
Dendrites . . . . .	T142	DNA Methylation . . . . .	1.3, M16, M29, M32, M122, T183, T271, W110, W144
Dendritic Remodeling . . . . .	T217	Dog . . . . .	M162
Dendritic Spine . . . . .	M236, T93, T183, W207	Dopamine . . . . .	6.3, 9.1, 42, 61.4, M30, M135, M183, M201, M205, M207, M212, M234, M241, M250, M268, M279, T2, T32, T184, T200, T235, T264, T267, W43, W66, W151, W160, W184, W214, W223, W232, W240
Dentate Gyrus . . . . .	M84, T19, T174, W10	Dopamine (D2, D3) Receptors . . . . .	T114, T201, T239, T245, W69, W189
Depression . . . . .	2.2, 2.3, 10.1, 10.3, 17.4, 24, 33.1, 33.2, 40.2, 43.1, 48.1, 53.3, 57, 57.4, M22, M53, M71, M73, M75, M76, M80, M83, M89, M94, M107, M109, M115, M118, M120, M122, M127, M128, M129, M130, M132, T11, T116, T21, T27, T28, T30, T151, T69, T77, T80, T114, T120, T121, T126, T127, T130, T134, T136, T138, T167, T266, W4, W22, W38, W75, W78, W82, W94, W98, W104, W108, W112, W113, W115, W122, W126, W133, W135, W139, W142	Dopamine 2 Receptor . . . . .	T18, T210
Depression Inflammation Cytokine. . . . .	M114	Dopamine 3 Receptor Imaging. . . . .	T239, W109
Depression Risk. . . . .	W86	Dopamine Agonists . . . . .	M83
Depression Subtypes . . . . .	49.4, M125, W89	Dopamine D3 Receptors . . . . .	M239, M254
Depression Treatment Response. . . . .	10, M86, T129	Dopamine Receptors . . . . .	M273
Depressive Symptoms . . . . .	M93	Dopamine Release . . . . .	W109
Desensitization . . . . .	W193, W233	Dopamine System . . . . .	M91
Design . . . . .	23	Dopamine Transporter. . . . .	M270, W58, W225, W242
Desvenlafaxine. . . . .	M82	Dopamine-Deficient Mice . . . . .	W214
Development. . . . .	23.1, 28.3, M190, T12	Dopaminergic Modulation . . . . .	T241
Developmental. . . . .	22	Dopaminergic System . . . . .	31.4, 33.2, T109
Developmental Neuroscience . . . . .	T90, W188	Dorsal Striatum . . . . .	16.2, M66
Developmental Psychopathology. . . . .	23.3, 27.1, 28, 29, M143, T250	Dorsolateral Prefrontal Cortex . . . . .	31.2, M171, M216, W201
Developmental Trajectories . . . . .	6.2, 11.2	Dose-Response Analyses . . . . .	2, 2.3, M276
Dextromethorphan/Quinidine . . . . .	M274	Downregulation. . . . .	50.4
DHCR7. . . . .	W51	DREADD Receptor . . . . .	W240
Diagnosis . . . . .	T75, W163	DREADDs. . . . .	42.3, T178, W69
Diet Induced Obesity. . . . .	32, T98, T99, W118	Drebrin. . . . .	W250
Dietary Supplement. . . . .	W228	Drug Abuse. . . . .	T264, W251
Dieting . . . . .	M60	Drug Addiction . . . . .	20, 37, 50, 50.1, 53.2, T43, T229, T276, W273
Diffusion MRI. . . . .	T37, T154	Drug Cues. . . . .	T276
Diffusion Tensor Imaging (DTI) . . . . .	32.1, M45, M155, M165, T66, T88, T94, W4, W17, W32, W33, W136, W202	Drug Development . . . . .	M207
Diffusion Weighted Imaging . . . . .	7.1, M198	Drug Discovery . . . . .	M207
Digital Assessment. . . . .	T122	Drug Discovery - New Approaches. . . . .	25.1, T175
Digital Health Feedback System . . . . .	57.4	Drug Discovery/Development. . . . .	W193
		Drug Liking. . . . .	T166
		Drug Mixtures. . . . .	W234
		Drug Relapse. . . . .	T261, W168
		Drug Side Effects. . . . .	W221
		Drug Use . . . . .	M219
		D-Serine . . . . .	W165, W175

DSM-5 . . . . . T208  
 Duration of Untreated Psychosis . . . . . 27.3, 61.1, 61.2,  
 61.3, 61.4  
 Dynamical System . . . . . 13.1  
 Dynorphin . . . . . M240, T142, T277  
 Dysphoria . . . . . M25  
 E/I Imbalance . . . . . 17.3  
 Early Auditory Information Processing . . . . . T199  
 Early Detection . . . . . 47, W44  
 Early Identification of Risk . . . . . M37, T225, W33  
 Early Intervention . . . . . 47, 61  
 Early Life Stress . . . . . 1.2, 29.2, 46.1, T11, T38,  
 T138, W27, W159  
 Early Psychosis . . . . . 27.3, M189, T208  
 Early Rearing . . . . . 55  
 Eating . . . . . M59, M125  
 Eating Disorders . . . . . M58, M61, T100,  
 W54, W55, W57, W58  
 Ecological Momentary Assessment . . . . . M4, M81  
 Education . . . . . 39  
 EEG Biomarkers . . . . . 10.1, 56.4, 57.1, M26,  
 M47, M72, M104, M163,  
 T110, W126, W174  
 EEG/ERP Electrophysiology . . . . . 15, 19.2, 56.3, 60.2,  
 60.4, M47, M117, T181,  
 T192, T205, T216, T275  
 Effective Connectivity . . . . . W59  
 Efficacy and Safety . . . . . 41.4  
 Effort-Cost Benefit Task . . . . . 33.1, T187, W108  
 Eicosanoids . . . . . W90  
 Electric Field Modeling . . . . . T145, T151  
 Electroconvulsive Therapy (ECT) . . . . . 7.4, M98, M103,  
 T114, T130, T144, T151,  
 W100, W102, W142  
 Electroencephalography (EEG) . . . . . 10, 24.1, 50.2,  
 56.2, T85, W44, W190  
 Electron Microscopy . . . . . W277  
 Electronic Cigarette (E-Cigarette) . . . . . T81  
 Electrophysiology . . . . . 3.2, 3.4, 37.3, 56, M142, M240,  
 M258, M271, T2, T12, T139,  
 T152, T211, T273, W86, W268  
 Emotion . . . . . M81  
 Emotion Cognition Integration . . . . . T118  
 Emotion Modulation . . . . . 4, T4  
 Emotion Processing . . . . . M86, T275  
 Emotion Recognition . . . . . W222  
 Emotion Regulation . . . . . 49.4, 50.2, M218, T100,  
 T118, W20, W40  
 Emotional Memory . . . . . W153  
 Emotional Pain . . . . . 43.1  
 Emotional Processing . . . . . T71, W103

Emotional Regulation . . . . . 29.2, T9, T21, T30  
 Emotional Stress . . . . . 9, T84  
 Endocannabinoid . . . . . 16.2, 41.1, 41.2, 41.3, M8, M145,  
 M275, M282, T68, T98, T99, W196  
 Endogenous Opioids . . . . . W124  
 Endophenotype . . . . . M174, M214, T213  
 Engram . . . . . 53, 53.4  
 Environmental Enrichment . . . . . M229  
 Epidemiology . . . . . T153, W146  
 Epigenetic . . . . . 1.2, 1.3, 46, M16, M152  
 Epigenetic Regulation . . . . . T277  
 Epigenetics . . . . . 1, 6.1, 10, 10.3, 20.4, 46.1, M18,  
 M32, M69, M269, T26, T38, T48,  
 T60, T183, T230, T231, T278,  
 W27, W144, W196, W265  
 Epilepsy . . . . . 42.1, M152  
 ERK . . . . . W167  
 ERP . . . . . 19.3, T199  
 Error Processing . . . . . M11  
 Errors . . . . . W203  
 Escitalopram . . . . . M82, M88  
 Esketamine . . . . . W76, W93, W104, W107  
 Estradiol . . . . . 44.3, W72, W98  
 Estrogen . . . . . 44.1, 44.2, W247  
 Estrogen Synthesis . . . . . 44  
 Ethanol . . . . . 54.1, M230, W263  
 Ethical Issues . . . . . 45  
 Ethics . . . . . 45.1, 45.3  
 Event-Related Potential . . . . . 19.3, 60, T42, T220, W183  
 Excessive Sleepiness . . . . . M222  
 Excitability . . . . . 9, M177  
 Excitation-Inhibition Balance . . . . . T142  
 Excitatory Synapses . . . . . W274  
 Executive Function . . . . . 29.4, M5, M50, T17, T57  
 Executive Network . . . . . 61.3  
 Exosome . . . . . 20.1  
 Expectation Bias . . . . . M265  
 Experience Dependent Plasticity . . . . . W40  
 Experimental Design . . . . . M265  
 Experimental Medicine . . . . . T187  
 Experimental Therapeutics . . . . . T171  
 Exploration . . . . . T69  
 Exposure Therapy . . . . . 4.4, T3, T8  
 Exposure-Response Model . . . . . T263  
 Expression Quantitative Trait Loci . . . . . T280  
 Extended Amygdala . . . . . 55.1  
 Extended Release Formulations . . . . . 35, 35.1  
 Extended Reward Network . . . . . 37.4  
 Extended Social-Affective Default Network . . . . . W38

Extended-Release Depot . . . . .	T209	Fractional Anisotropy . . . . .	M165
Extended-Release Naltrexone . . . . .	35.2	Fragile X . . . . .	T219
Externalizing Disorders . . . . .	29.4	Fragile X Syndrome . . . . .	56, 56.1, 56.2, 56.4, W167, W192
Extinction . . . . .	4, T53	Frontal Cortical . . . . .	M159, T188
Extinction Learning . . . . .	W268	Frontostriatal . . . . .	T137
Eye-Tracking . . . . .	T85	Frustration Tolerance . . . . .	T9
F-18 PET Imaging . . . . .	31.3	Frustrative Non-Reward . . . . .	W136
FAAH . . . . .	41, T5	Functional Capacity . . . . .	T182, W172
Face Emotion Processing . . . . .	M182, T65	Functional Connectivity . . . . .	4.3, 25.4, 47.4, 55, M223, T196, W21, W38, W166, W229, W260
Factor Analysis . . . . .	W249, W267	Functional Genomics . . . . .	T203
Familial Risk . . . . .	T24, T37	Functional Impairment . . . . .	5.1, M54, M109
Familiality . . . . .	M174	Functional Magnetic Resonance Imaging (fMRI) . . . . .	4.3, 5, 5.3, 7, 10, 10.2, 12.1, 17, 24.1, 24.4, 29.3, 33.1, 33.3, 36.2, 49.1, 49.4, 60.3, M6, M11, M26, M44, M58, M83, M125, M127, M134, M139, M141, M151, M171, M173, M180, M197, M227, M252, M259, M266, M272, M276, T4, T14, T21, T50, T82, T86, T102, T105, T118, T120, T143, T147, T150, T179, T194, T216, T238, T240, T259, T276, W19, W35, W54, W56, W60, W61, W63, W74, W103, W111, W131, W170, W191, W200, W201, W226, W233
Fast-Acting Antidepressant . . . . .	17, 17.2, 46.1, M131	Functional Neuroimaging . . . . .	3.4, 5.3, 7.1, 12, 49, M46, T233, T254, W13, W37, W98
Fatty Acid Amide Hydrolase . . . . .	41.1, 41.3	Functional Organization . . . . .	16.1
Fatty Acid Amide Hydrolase Inhibitor . . . . .	41.4	Functional Outcomes . . . . .	T221
Fatty Acids . . . . .	W90	Functional Selectivity . . . . .	W193
Fear . . . . .	4, M134, T194, W39	Functioning . . . . .	M211
Fear Conditioning . . . . .	4.2, 53, 53.3, 53.4, T71, W7, W10	GABA . . . . .	17.3, 17.4, M12, M62, M148, T59, T142, W248
Fear Extinction . . . . .	4.1, 4.4, 41, 41.3, M12, T70, T178, W9, W10	GABA MRS . . . . .	W35
Fear Generalization . . . . .	M23, W12	GABA Neuron . . . . .	T252
Fear Memory . . . . .	M13, M145, W7	GABA Transmission . . . . .	M49, T52, T176, T243
Fear of Flying . . . . .	T8	GABAA . . . . .	W167
FEAST . . . . .	W142	GABA-A Receptors . . . . .	9.2, M108, T141, T258, W116
Feature Combination . . . . .	7.3	GABAergic Cells . . . . .	W34
Feature Selection . . . . .	T271	GABAergic Circuitry . . . . .	33.2, 40.3, T23
Feeding . . . . .	30.2	GABAergic Interneurons . . . . .	19, 19.4, 25.3
Feeding Behavior . . . . .	M55	GABRA2 . . . . .	T251, T265
Female . . . . .	38.1, W122, W135	GAD65 mRNA . . . . .	M62
Fetal Brain Development . . . . .	W52	GAD67 mRNA . . . . .	M62
Fetal Neurobehavior . . . . .	W50	Galantamine . . . . .	W141
Fine Mapping . . . . .	W239	Galantamine-Memantine Combination . . . . .	W220
First Episode Psychosis . . . . .	61, 61.2, 61.4, M189, T197, W183, W195	Gambling . . . . .	W69
First Episode Schizophrenia . . . . .	42.3, 52.1, 61.3, W204	Gamma Oscillation . . . . .	40.3, 56.1, T212
FKBP5 . . . . .	T38	GCF21 . . . . .	M162
Fluorodeoxyglucose . . . . .	M157, M179	Gender Differences . . . . .	T161, T239
fMRI KO Rat . . . . .	W192		
fMRI Biomarkers . . . . .	10.2		
fMRI Faces Paradigm . . . . .	M114		
fMRI Functional Connectivity . . . . .	12.1, 55.2, M49, M96, M133, M139		
fMRI/Imaging Genetics . . . . .	M85		
FMRP . . . . .	M194		
fMRS . . . . .	T186		
Focal Electrically Administered Seizure Therapy . . . . .	W142		
Folate . . . . .	W205		
Forced Swim Test . . . . .	W119		
Forebrain . . . . .	55.1		



Gender Dysphoria . . . . . W226  
 Gender Identity . . . . . W226  
 Gene Co-Expression . . . . . M193  
 Gene Editing . . . . . 45.3  
 Gene Expression . . . . . 1.1, 54.3, 59, 59.2, M13,  
 M111, M136, M251, T60,  
 T279, W208  
 Gene Manipulation . . . . . 45.1  
 Gene Regulation . . . . . T38, W82  
 Gene X Environment Interaction . . . . . M190  
 Gene-Environment Interaction . . . . . 1.4, M171  
 Genetic Architecture . . . . . T67  
 Genetic Mouse Model . . . . . 43.2, T211, W42  
 Genetic Risk . . . . . M193  
 Genetic Risk Factor . . . . . 6.2, T241  
 Genetically Modified Model . . . . . 45.2  
 Genetics . . . . . 21, 26, M187, T39, T60, T90, T201,  
 T202, W276  
 Genome Editing . . . . . 45.2  
 Genome-Wide Association Study (GWAS) . . . . M85, M88,  
 M92, M99, M188, M244,  
 T191, T213, T265, T280,  
 W101, W145, W148,  
 W238, W239  
 Genomics . . . . . T119, T202  
 Geriatric . . . . . W4  
 Geriatric Depression . . . . . W102  
 Ghrelin . . . . . T259  
 Global Assessment Of Functioning (GAF) . . . . . M208  
 Global Changes . . . . . M54  
 Global Mental Health . . . . . 34  
 Global Outreach . . . . . 39  
 GLT-1 . . . . . W254  
 Glucocorticoid Receptor . . . . . T25, W36  
 Glucocorticoid Receptor Gene . . . . . M37  
 Glucocorticoids . . . . . M275, W158  
 GluN2B . . . . . W168  
 Glutamate . . . . . 14.3, 16.3, 42, 47.2, 47.4, 52.1,  
 61.4, M76, M100, M165, T186,  
 T200, W140  
 Glutamate GABA . . . . . 17, 19, 52, 52.2, T47  
 Glutamate Homeostasis . . . . . 16.1, M281, W254  
 Glutamate Receptor Activity . . . . . T133  
 Glutamate Transport . . . . . M281  
 Glutamatergic Synapses . . . . . M185, M194  
 Glutamine . . . . . M71  
 Glutathione . . . . . M176  
 Glycosylation . . . . . T185  
 Glymphatic Clearance . . . . . M156  
 GLYX-13 . . . . . T79, W75

Goal Maintenance . . . . . M186  
 Goal-Directed Behaviors . . . . . M66  
 Golden Hours . . . . . 51.2  
 Gonadal Hormones . . . . . 48  
 GPCR . . . . . 25.1, 43, T31, T146  
 GPS . . . . . T50  
 Graph Theory . . . . . T143, T238  
 Gray Matter Volumes . . . . . M42, T207  
 GT-tg Mouse Model . . . . . T97  
 Guanfacine . . . . . T54, T182  
 Gut Microbiome . . . . . M138, M237, W112  
 Gut Microbiota . . . . . W71  
 Gut-Brain Axis . . . . . T99, T259, W71  
 GWAS Loci . . . . . T35  
 Habenula . . . . . 38.4, M85, T231  
 Habit . . . . . T250  
 Habitual Behavior . . . . . 59.4  
 Habituation . . . . . W74, W130  
 Hallucinogens . . . . . M274  
 Haloperidol . . . . . W214  
 HAM-D . . . . . W97  
 Healthy Individuals . . . . . 31.4  
 Healthy Subjects . . . . . M5, T190  
 Heart Rate . . . . . M153, W272  
 Heart Rate Variability . . . . . W259  
 Hedonic Ingestion . . . . . T164  
 Hemodynamic Response Function . . . . . M161  
 Hepatitis C . . . . . M257  
 Heritability . . . . . T67, W101  
 Heroin . . . . . M249  
 Heroin Self-Administration . . . . . W87  
 Heterogeneity . . . . . W89  
 High Fat Diet . . . . . 32.2, W118  
 High Risk Psychosis . . . . . 11.4, 13.2, 27.1  
 Higher Level Cognition . . . . . 3, 3.2  
 Hippocampal Subfields . . . . . M27, M103, W161  
 Hippocampal Volume . . . . . 61, 61.2, W161  
 Hippocampal-Prefrontal . . . . . T178  
 Hippocampus . . . . . 20.2, 44.3, 47, 47.2, 47.3, 47.4,  
 53.1, 53.2, 53.3, M23, M98, M122,  
 M169, M224, M248, T19, T66, T226,  
 T228, W2, W10, W45, W159, W161,  
 W275, W277  
 Hippocampus-mPFC Pathway . . . . . 19.1  
 Hispanic/Latinos . . . . . T168  
 HIV . . . . . 32.3, M140, T27, T227, T233, W264  
 HIV-Associated Neurocognitive Disorder . . 32.3, T97, W73  
 HNK . . . . . W106  
 Homeostasis . . . . . 21, 21.1

Homeostatic . . . . .	T219	Inferior Frontal Gyrus . . . . .	M59
Homeostatic Plasticity . . . . .	14.2, W274	Inflammasome . . . . .	M115
Hormone . . . . .	48.3	Inflammation . . . . .	13.2, 22, 22.2, 32, 44.4, 58, 58.2, M3, M71, M90, M93, M101, M112, M129, M166, M189, M237, T26, T46, T94, T140, T55, T135, T167, W71, W90, W215
HPA Axis . . . . .	T25	Inflammatory Cytokines . . . . .	22.1, 58.4, T195
Human Brain Imaging . . . . .	31.3, 46.3, M127, M239	Inflammatory Disturbances . . . . .	W217
Human Clinical Trial . . . . .	56.4, M113, T246	Inflammatory Markers . . . . .	16.1, 22.3, 32.3, M213, W172
Human Connectome . . . . .	7, 7.1	Infralimbic Cortex . . . . .	W268
Human Genetics . . . . .	34, M80, M278, T76, W88, W242	Inhibitory Control . . . . .	M11, M59, W65
Human Neuroimaging . . . . .	4.2, 12.2, 15, 23.2, 24, 24.1, 24.3, 27.1, 33, 37.4, 49.2, M35, M68, M78, M239, M242, T17	Inhibitory Synaptic Transmission . . . . .	T141
Huntington's Disease . . . . .	16, 16.2, W70	Innate Alarm System . . . . .	W25
Hydrocortisone . . . . .	51.2, W9	Innate Immunity . . . . .	M1
Hydroxynorketamine . . . . .	M132, W129, W135	Inpatient . . . . .	M90
Hyperalgesia . . . . .	M160	Insight . . . . .	W181
Hypersexual Disorder . . . . .	W225	Insomnia . . . . .	T27
Hypnosis . . . . .	W53	Instrumental Learning . . . . .	T262
Hypothalamic-Pituitary-Adrenal Axis . . . . .	T59, W100	Insula . . . . .	12, 12.1, M94, M125, M240, T4, T233, T255, W52
Hypothalamus . . . . .	38.1, 38.3	Insula Connectivity . . . . .	12.3, 12.4, 14.4
Hypoxia . . . . .	M2	Insulin Resistance . . . . .	46, 46.1, 46.3, T28, T137, T138, W212
IFITM . . . . .	M204	Insulin-Like Growth Factor 1 . . . . .	M31
Imaging . . . . .	61.4, M166	Integrative Health . . . . .	M225
Imaging Genetics . . . . .	W186	Interim Treatment . . . . .	35.3
Immobility . . . . .	W143	Interleukin-1 . . . . .	T52
Immune . . . . .	T127	Interleukin-33 . . . . .	M137
Immune Biomarkers . . . . .	58, T84, W50	Internalizing Disorders . . . . .	T89
Immune Markers . . . . .	8, M164, M204, M213, M215	Internet . . . . .	57.2
Immune Modulation . . . . .	M262	Interneurons . . . . .	59.3, M209
Immune System . . . . .	M170	Interoception . . . . .	T102, T157, T233, W56
Immunohistochemistry . . . . .	W185	Interpersonal Conflict . . . . .	T71
Impulse Control . . . . .	T125	Intracranial Self-Stimulation . . . . .	T260
Impulsiveness . . . . .	M67	Intransal . . . . .	M28
Impulsivity . . . . .	M44, M66, M136, M151, M218, M272, T100, T109, T198, T240, W55, W62, W65, W67, W68, W69, W232, W238	Intravenous Administration . . . . .	M97
Imputation . . . . .	T60	Intravenous Drug Self-Administration . . . . .	M280, W230
In Vivo . . . . .	T224	Intrinsic Excitability . . . . .	W274
In Vivo Calcium Imaging . . . . .	30.3, M120, M126, W11, W12	Intrinsic Period . . . . .	40.1
In Vivo Imaging . . . . .	30, 32, W64	Ion Channels . . . . .	W198
Inattentive Symptoms . . . . .	W55	Iowa Gambling Task . . . . .	M264
Inbred Mouse Strain . . . . .	21.4, T61	Iron . . . . .	T253
Incentive Motivation . . . . .	M250, M271, W241	Irregular Sleep/Wake Rhythm Disorder . . . . .	M220, M221
Incubation . . . . .	14	Irritability . . . . .	24, 24.3, T9, T14
Incubation of Cocaine Craving . . . . .	14.1, 14.2, 14.3	Ischemia-Reperfusion Injury . . . . .	M2
Individual Differences . . . . .	12.1	JDTic . . . . .	M224
Individual Variability . . . . .	T151, T243	Joint Independent Component Analysis . . . . .	T216
Indoleamine 2,3-Dioxygenase . . . . .	T135	JZP-110 . . . . .	M222
Infant . . . . .	29.1, W50	Kalirin . . . . .	T222
Infection . . . . .	W215		

Kappa Opioid . . . . . W157  
 Kappa Opioid Receptor . . . . . 43.4, M240, M268,  
 T124, T277, W5, W266  
 Ketamine . . . . . 2, 2.1, 2.2, 2.3, 2.4, 16.4, 17.2, 53.3,  
 M28, M77, M87, M95, M96, M97,  
 M100, M106, M107, M116, M121,  
 M130, M132, T79, T111, T144, T162,  
 T205, T212, T247, W20, W89, W92,  
 W103, W106, W107, W122, W135,  
 W140, W151  
 Kinome Array . . . . . 16.3  
 KO mice . . . . . W281  
 Kv3 Channels . . . . . 42, 42.2, 59.3  
 Kynurenic Acid . . . . . M100, T77, T192, W176  
 Kynurenine Pathway . . . . . M82, T77, T135, T226, W93, W220  
 Kynurenines . . . . . M101  
 Lamotrigine . . . . . T123, W161  
 Language . . . . . W21  
 Large Scale Networks . . . . . 12.4, M46, T147  
 Late-Life Depression . . . . . M86, M99, T1, T176, T177  
 Latency of Acoustic Startle . . . . . W211  
 Latent Class Analysis . . . . . T165  
 Lateral Habenula . . . . . W64, W132  
 Lateral Hypothalamus . . . . . W11  
 Lateral Orbitofrontal Cortex . . . . . T98, T106  
 Lateral Septum . . . . . M23  
 Learning . . . . . W133  
 Learning and Memory . . . . . T186, W247, 53.2  
 Learning Health System . . . . . W137  
 Left-Truncation . . . . . M265  
 Leukocyte Telomere Length . . . . . W110  
 Leukocytic miRNA . . . . . 13.1  
 LH . . . . . W106  
 Life Stress . . . . . T56  
 Light Therapy . . . . . T6, T134  
 Limbic Cortex . . . . . M94  
 Linkage . . . . . W239  
 Linked ICA . . . . . W256  
 Lipid Rafts . . . . . T146  
 Lipids . . . . . T278, W88, W172  
 Lipopolysaccharide . . . . . M93  
 Lithium . . . . . M52, T112, T160, W96  
 Lithium Response . . . . . M123, W111  
 Local Field Potentials . . . . . M55  
 Locus Coeruleus . . . . . 12.3, M258, T134, T158  
 Long Noncoding RNA . . . . . 20, 20.2, 20.4  
 Long Term Potentiation . . . . . 60, 60.1  
 Long-Acting Injectable Antipsychotics . . . . . M199, T156, W85  
 Longitudinal . . . . . 57.2, T223  
 Longitudinal Analysis . . . . . T78, W14

Longitudinal Imaging . . . . . 11.1, 11.2, M43, W201  
 Longitudinal Study . . . . . M22, T39, W183  
 Long-Term Safety . . . . . T209  
 Long-Term Treatment . . . . . M95, M208  
 Long-Term Trial . . . . . T263  
 Loss . . . . . W123  
 Low Birth Weight . . . . . M155  
 LPS . . . . . M77  
 Lumateperone . . . . . M76  
 Lurasidone . . . . . T78, W121, W172  
 Macaque . . . . . 29.2, M162  
 Machine Learning . . . . . 5, 5.1, 18.3, 52.4, 57, 57.2,  
 57.3, M42, M55, M104, T155,  
 T163, T271, W229  
 Machine Learning Clustering . . . . . T121  
 MADRS . . . . . M110, T29, W104  
 Magnetic Resonance Imaging (MRI) . . . . . 11.4, 23.1, 27.2,  
 M25, M27, M42, M53,  
 M150, M200, M205, M257,  
 T112, T116, T136, T180,  
 T253, W128, W149, W271  
 Magnetic Resonance Spectroscopy . . . . . M12, T95, T123  
 Maintenance Treatment . . . . . M95  
 Major Depression . . . . . T128  
 Major Depressive Disorder (MDD) . . . . . 2.4, 10.4, 17,  
 24.4, 33.3, 49.1, 49.2, 49.3,  
 57.1, M20, M72, M79, M82, M103,  
 M104, M108, M112, M124,  
 M128, M256, T22, T56, T73,  
 T115, T141, T143, T145,  
 T148, T157, T234, W40, W79,  
 W80, W84, W95, W102,  
 W103, W109, W117, W120,  
 W124, W128, W132, W138, W140  
 Manganese . . . . . T185  
 Mania . . . . . W78, W125  
 Marijuana . . . . . M252, M256, M276, M282, T234, T268, W243  
 Marijuana Policy . . . . . W236  
 Marmoset . . . . . 45.2  
 Maternal Behavior . . . . . T138, W156  
 Maternal Depression . . . . . M266, W52  
 Maternal Immune Activation . . . . . 8, M176, M198, T91,  
 T108, W217  
 Maternal Sensitivity . . . . . T65  
 Maternal Separation . . . . . M45  
 MDPV . . . . . W230  
 Mechanism of Action . . . . . 2, M96, M98  
 Medial Forebrain Bundle . . . . . M110  
 Medial Prefrontal Cortex . . . . . 37.1, M12, M17, M24,  
 M48, M209, T211, T258,  
 W62, W154  
 Medication . . . . . 51.1, W224

Medication Development . . . . .	M270	Mismatch Negativity . . . . .	19.4, M214, T42
Mediodorsal Thalamus . . . . .	3.1, 37.1	Mitochondria . . . . .	T113, T230, W169
Medium Spiny Neuron . . . . .	W248, W261	Mitochondrial DNA . . . . .	W110, W159
MEF2C . . . . .	M194	Mitochondrial Dysfunction . . . . .	W73
MEG . . . . .	47.1, M191	Mitochondrial Function . . . . .	T204
Memory . . . . .	3.3, 4, 47.3, 53, 53.3, 53.4, T15, T132, T175, W2, W208	Mixed Features . . . . .	W81
Memory Consolidation and Extinction . . . . .	51	MMN . . . . .	19.3, T199
Memory Encoding and Retrieval . . . . .	50.1, M141, W12	MMP9 . . . . .	40.3
Memory Loss . . . . .	W3	Mobile Technology . . . . .	T80
Memory Reconsolidation . . . . .	4, 4.1, 4.4, M277, T8	Model-Free and Model-Based Learning . . . . .	57.2
Menopause . . . . .	W2, W3	Moderators . . . . .	T87
Mental Health Service Use . . . . .	57.4	Molecular Mechanisms . . . . .	51, M262, T229
Mentalizing . . . . .	W210	Monetary Incentive Delay Task . . . . .	T187
Mesolimbic Circuitry . . . . .	T139	Monoamine Oxidase A . . . . .	M29, T180
Mesolimbic Reward Circuitry . . . . .	T279	Monoamines . . . . .	T152
Meta-Analysis . . . . .	61.1, M11, M263, T58, T77, W13, W19, W24, W147, W151, W186	Mood . . . . .	21.3, 48.3
Metabolic Function . . . . .	W177	Mood and Addiction . . . . .	W244
Metabolic Safety . . . . .	T189	Mood Disorder . . . . .	11.1, 11.4, 16, 16.4, 33, 40, 46.2, 49, M102, M111, T63, T132, T160, W15
Metabolic Side Effects . . . . .	M200, M217, T210	Mood Disorder Subtypes . . . . .	M70
Metabolism . . . . .	W263	Morphine . . . . .	M279, T244, W257, W273
Metabolites . . . . .	T129, T224	Mortality . . . . .	M181
Metabolomics . . . . .	T119, W92, W212	Motivation . . . . .	30, 30.1, 43.4, T267, W178
Metabotropic Glutamate Receptor . . . . .	46.1, T237, T249, W253	Motivational . . . . .	T122
Meta-Cognition . . . . .	W181	Motor Activity . . . . .	21.1
Methadone Maintenance Treatment . . . . .	W259	Motor Behavior . . . . .	W34
Methamphetamine . . . . .	14.4, M228, M242, T253	Mouse Behavior . . . . .	M279
Methionine . . . . .	W208	Mouse Model . . . . .	22.2, M34, M185, M221, T19, T260, W159
Methohexital . . . . .	T144	mPFC . . . . .	W16, W64
Methylphenidate . . . . .	T63	MPTP . . . . .	31.1, W162
Mexican Americans . . . . .	W276	MR spectroscopy . . . . .	M40, W200, W263
mGlu5 . . . . .	M154	MR-PET . . . . .	M253
mGluR5 Receptors . . . . .	M147	mtDNA . . . . .	T204
Mice . . . . .	17.1, T12, T256	mTOR . . . . .	M132
Microbiota-Gut-Brain Axis . . . . .	W107	mTORC1 . . . . .	M130
Microdialysis . . . . .	W108	Mu Suppression . . . . .	W174
Microglia . . . . .	22.2, 58.1, 58.2, T148, T177, W227	Multi-Episode Schizophrenia . . . . .	W221
Microglia Dystrophy . . . . .	54.1	Multi-Modal . . . . .	W256
Microglia Priming . . . . .	54.1	Multimodal Neuroimaging . . . . .	52, 52.4, T163
Microglial Activation . . . . .	M230, W105, W227	Multi-Site MRI . . . . .	W256
MicroRNA (miRNA) . . . . .	6.1, 13, 13.1, 13.3, 20, T48	Multivariate Connectome-Wide Association Study . . .	M39
Microtubule . . . . .	M203, W207	Mu-Opioid Receptor Agonist . . . . .	T166
Migraine . . . . .	M160	Mu-Opioid Receptors . . . . .	25.2, 43.1, M231, W119, W233, W239, W244, W255, W281
Mild Cognitive Impairment due to AD . . . . .	M50, M52, W184	Muscarinic Acetylcholine Receptor . . . . .	T193, W113
Mild Traumatic Brain Injury . . . . .	51.3, M157	Muscarinic Receptors . . . . .	W47
Mindfulness . . . . .	M18	Mutation . . . . .	W164
Minocycline . . . . .	M213		

MVPA . . . . . W147  
 Myelin . . . . . M203, T61  
 N-Acetylaspartate . . . . . M176, T95  
 N-Acetyl-Cysteine . . . . . T29  
 Naltrexone . . . . . 35.1, M260, T251, W87  
 Narcolepsy . . . . . M222  
 Negative Affect . . . . . 43.4, W266  
 Negative Symptoms . . . . . M188, T190, T195  
 Neocortical Hyperexcitability . . . . . 56, 56.1  
 Neonatal . . . . . 11  
 Network Analysis . . . . . M124, M197, T143, W19  
 Networks . . . . . 23.1  
 Neural Activity . . . . . M261  
 Neural Circuitry . . . . . 14, M84  
 Neural Circuits . . . . . 30, 38, 38.1, 43.3  
 Neural Network Connectivity . . . . . M41  
 Neural Oscillations . . . . . M186  
 Neural Plasticity . . . . . 60.3, M91  
 Neural Stem Cell . . . . . M74  
 Neural-Cardiac Interface . . . . . 50.4  
 Neuregulin-3 . . . . . 20.2  
 Neuroactive Steroid . . . . . W116  
 Neuroanatomy . . . . . W134  
 Neurobehavioral Disorders . . . . . 30.4  
 Neurobiology . . . . . 48.1  
 Neurocircuitry . . . . . W57, W149  
 Neurocircuits . . . . . M241, W66, W86  
 Neurocognition . . . . . 52.4, W206  
 Neurocognitive Functioning . . . . . M174, T165  
 Neurodegeneration . . . . . M213, W168, W169, W280  
 Neurodegenerative Disease . . . . . 31.1, T155, W164  
 Neurodevelopment . . . . . 1.2, 27, 29.2, M176, W149  
 Neurodevelopmental Disabilities . . . . . 56, 56.3  
 Neurodevelopmental Disorders . . . . . 56.1, M194, W28, W146  
 Neuroendocrine . . . . . M1  
 Neuroendocrinology . . . . . 51.3, M34, T138  
 Neurofilament . . . . . M203  
 Neurogenesis . . . . . M164, W20  
 Neuroimaging . . . . . 5, 7.4, 11, 27.2, 28.2, 50.3, M109, W57, W173  
 Neuroimmune . . . . . 54.3, M230, T52, W280  
 Neuroimmune Interaction . . . . . M262  
 Neuroinfection . . . . . T161  
 Neuroinflammation . . . . . 16, 22.4, 32.2, 40.3, 46, 46.2, 54, 54.1, 54.2, 58.1, 58.3, M189, M198, M217, M253, M281, T29, T33, T161, T172, T281, W36, W105, W270  
 Neuroleptic Malignant Syndrome . . . . . W163  
 Neurological Disorders . . . . . M102

Neuromarkers of Illness . . . . . 7.2  
 Neuromodulation . . . . . 18, 18.2, 33, 33.4, 36, M104, T31, T128, W53  
 Neuronal Activity . . . . . 3, 3.1  
 Neuronal Biomarkers . . . . . 50  
 Neuronal Culture . . . . . W75  
 Neuronal Ensemble . . . . . 50.1  
 Neuronal Epigenome . . . . . T91  
 Neuronal Maturation . . . . . W243  
 Neuropathic Pain . . . . . 25.3  
 Neurophysiology . . . . . M241, T125  
 Neuroplasticity . . . . . 60, 60.4, M10, M189, T56, T101, W197, W275  
 Neuropsychiatric . . . . . 22.4  
 Neuropsychiatric Disorders . . . . . 6.2, T220  
 Neuropsychiatry . . . . . M159, W148  
 Neuropsychology . . . . . M81, M206, T86, W102, W243  
 Neuroscience Driven Nomenclature . . . . . 39  
 Neurosteroid . . . . . T169  
 Neurosurgery for Psychiatric Disorders . . . . . 18, 18.1  
 Neurotechnology . . . . . T97  
 Neurotransmitter Co-Release . . . . . W223  
 Neurotransmitters . . . . . T235  
 Neurotrophins . . . . . T140  
 Neurovascular . . . . . M139, W185  
 New Drug Development . . . . . W199  
 Next Generation Sequencing . . . . . M74, M123  
 NFkB . . . . . M204, W36  
 Nicotine . . . . . 20.2, M234, M260, M280, T81, W141, W203, W232, W264  
 Nicotine Addiction . . . . . M281, T44, T54, T241, T256, W269  
 Nicotine Dependence . . . . . 12.1, 12.4, 20.1, M33, M243  
 Nicotinic Acetylcholine Receptors . . . . . M234, M278, T44  
 NMDA . . . . . M28, M76  
 NMDA Antagonists . . . . . M96, T162, T198, W168, W200  
 NMDA Glutamate Receptors . . . . . T282  
 NMDA Receptor . . . . . 14.1, 19.3, 42, 42.1, M185, T199, T211, T212, W99, W163, W165, W175  
 Nociceptin . . . . . 30.2, 30.4, W245  
 Non-Coding . . . . . M202  
 Non-Coding RNA . . . . . 10.4, 20.3  
 Non-Human Primate (NHP) . . . . . 31.3, 45, 45.2, 45.3, M10, M143, M176, T272, W20, W162, W255  
 Non-Human Primate Model . . . . . 45.1, M198, W131, W245  
 Non-Medical Use . . . . . W258  
 Non-Pharmacological Therapy . . . . . T62  
 Nonverbal Reasoning . . . . . M41  
 Noradrenergic System . . . . . M14  
 Norepinephrine . . . . . M30, W15



Novel Endpoints . . . . .	T269	Oxidative Stress . . . . .	40.3, 46, M73, W121
Novel Targets . . . . .	T130	Oxytocin . . . . .	M134, T194, T218, T270, W156, W174, W210, W279
Novel Therapeutics . . . . .	M79, T62, T134, T169, T260	Oxytocin and Addiction . . . . .	W278
Novel Tool . . . . .	M67, M248	P2X7 . . . . .	M113
NTRK3 . . . . .	M10	P300 . . . . .	W179
Nucleus Accumbens (NAA) . . . . .	9.1, M126, M236, M278, M279, T53, T142, T229, T267, T282, W16, W62, W67, W68, W136, W250, W261	PACAP . . . . .	W23
Nucleus Accumbens Core . . . . .	14.1, T51	Pain . . . . .	25.1, 43.3, 43.4, M38, M75, M160, M232, T162, W147, W228, W255
Nucleus Accumbens Shell . . . . .	M65, T20, T252, W154	Pain Sensitivity . . . . .	T64
Obesity . . . . .	46.2, T18, T30, T137, T164, W60, W61	Paraventricular Nucleus of the Thalamus . . . . .	W130
Obsessive-Compulsive and Related Disorders . . . . .	M68	Parkinsonism . . . . .	T170
Obsessive-Compulsive Disorder (OCD) . . . . .	18, 18.1, 18.2, 18.3, M9, M11, M27, M28, M161, T3, T67, T76, T79, T87, T105, W6, W8, W16, W18, W26, W63	Parkinson's Disease . . . . .	45, T171, T172, W162, W164, W176, W184
Obsessive-Compulsive Symptoms . . . . .	T165	Parkinson's Disorder . . . . .	T192
Obstetric Complications . . . . .	1.4	Partial Agonist . . . . .	T245
Occupancy . . . . .	W189	Parvalbumin . . . . .	40.3, M209
Olanzapine . . . . .	T214	Parvalbumin Interneuron . . . . .	17.1, 42.2, T36
Olfaction . . . . .	M134	Parvalbumin Neurons . . . . .	M48, T212, W121
Olfactory . . . . .	T198	Patch . . . . .	W49
Oligodendrocytes . . . . .	T173	Patch Foraging . . . . .	T32
Omega-3 Fatty Acid . . . . .	T94, T149, T197, W29	Pathological Gambling . . . . .	T264
One-Carbon Metabolism . . . . .	W208	Pathophysiology . . . . .	47.2
Opiate . . . . .	M140, M249, M266, T244, T271, W250	Pathway Analyses . . . . .	16.3
Opioid . . . . .	25, M232, M235, M272, W94, W234, W251, W266	Pathways . . . . .	21.3
Opioid Agonist Treatment . . . . .	35, 35.1, 35.4, M232, W228	Patient Functioning . . . . .	M208
Opioid Antagonist Treatment . . . . .	35, 35.1, M255	Patient Reported Outcomes . . . . .	W76
Opioid Dependence . . . . .	25.2, 35, 35.2, 35.3, 35.4, M259, T263	Pavlovian . . . . .	T262
Opioid Overdose . . . . .	W281	Pavlovian Conditioning . . . . .	M242, T101, W15, W231
Opioid Receptors . . . . .	43.3, W80	PDE10A . . . . .	W199
Opioid Side-Effects . . . . .	25.1, 25.2	Pediatric . . . . .	T162, W30
Opioid System . . . . .	25.1	Pediatric PTSD . . . . .	M43
Opioid Withdrawal . . . . .	M235	Pentosan Polysulfate Sodium . . . . .	T46
Optochemogenetics . . . . .	43	Perceived Stress . . . . .	W259
Optogenetics . . . . .	12, 19.1, 30, 30.1, 30.3, 53.1, M24, M64, M241, M271, T12, T109, T158, T174, W66, W235	Perfusion . . . . .	23.1, 49.2, M60
Orbitofrontal Cortex (OFC) . . . . .	M109, M261, W136	Periaqueductal Grey (PAG) . . . . .	W25
Orexin . . . . .	M247	Perinatal Brain Injury . . . . .	22.4
Orexin Receptor Antagonist . . . . .	M220, M221, M247, T158	Perinatal Stress . . . . .	22, W31
Oscillation . . . . .	19, M191	Perineuronal Net . . . . .	40.3, T255
Oscillatory Activity . . . . .	3, 42.1, 57.1	Peripartum . . . . .	T65
Osteoprotegerin (OPG) . . . . .	16.4	Peripheral Blood Mononuclear Cells . . . . .	13
Overdose . . . . .	W234	Personal and Social Performance (PSP) . . . . .	M208, M211
		Personality . . . . .	M119, T21
		PET Resting Metabolism . . . . .	M5
		PET Tracer . . . . .	31
		PharmacoBOLD . . . . .	W200
		Pharmacogenetic Response . . . . .	M167
		Pharmacogenetics . . . . .	M88, M144, T251, W127
		Pharmacogenomics . . . . .	W127

Pharmacokinetics. . . . . W113, W269  
 Pharmacology . . . . . 59.2, T90, W57, W204  
 Pharmacotherapy. . . . . 59, M144, M181, M280, T74,  
 T249, T269  
 Phencyclidine . . . . . W178  
 Phenotypes . . . . . 25.4, M235  
 Phenotyping . . . . . 23, 23.2  
 Phosphodiesterase 1 Inhibitor . . . . . T172  
 Phosphodiesterase-4 (PDE4). . . . . T175  
 Phosphorus Magnetic Resonance Spectroscopy . . . . . T181  
 Phosphorylation . . . . . M196  
 Photometry . . . . . 30.1, M250  
 Physical Exercise . . . . . W45  
 Placebo Response. . . . . M262  
 Placenta . . . . . 1, 1.1, 1.2, 1.3, 1.4  
 Plasticity . . . . . M105  
 Polygenic Risk Score . . . . . 1.4, 21.2, M37, M171  
 Polygenic Scores . . . . . M168  
 Polymorphism. . . . . W242  
 Polypharmacy . . . . . T184  
 Population Genetics. . . . . W148  
 Population Pharmacokinetics . . . . . M199  
 Positive Allosteric Modulators . . . . . 42.1, M108, T193, W141  
 Positive and Negative Syndrome Scale . . . . . T206  
 Positron Emission Tomography (PET) . . . . . 58.3, M148,  
 M154, M201, T235, T239,  
 W124, W233, W253, W266  
 Positron Emission Tomography (PET) Imaging . . . . . 42.3, 54,  
 58.4, 61, M7, M113, M135,  
 M147, M239, M254, T16, T33,  
 T45, T82, T133, T155, T237,  
 T245, W1, W91, W105, W109,  
 W157, W189, W270  
 Postmortem. . . . . M128, T193, W213, W219  
 Postmortem Brain Tissue. . . . . 52.3, M136, M195, M196,  
 T38, W96, W185, W198  
 Postmortem Human Brain. . . . . M204, M216  
 Postpartum Anxiety. . . . . W97  
 Postpartum Depression . . . . . T2, W97, W116  
 Posttraumatic Stress Disorder (PTSD) . . . . . 4.3, 24, 24.4,  
 51, 51.1, 51.2, 51.3, 51.4, 53, 53.4,  
 M1, M3, M12, M14, M15,  
 M16, M18, M19, M20, M21, M22,  
 M24, M25, M29, M30, M104, T6,  
 T25, T60, T70, T72, T121, T143,  
 T169, T225, T254, T270, W9, W14,  
 W15, W19, W20, W22, W25, W74,  
 W99, W112, W153  
 Pragmatic Analysis . . . . . 57  
 Prairie Voles . . . . . M228  
 Pramipexole . . . . . M83, W109  
 Prazosin . . . . . M14

Precision Medicine . . . . . 18.2, T116  
 Precision Medicine for Depression . . . . . 16.1  
 Precision Medicine for Mood Disorders . . . . . M113, T147,  
 W137  
 Precision Psychiatry. . . . . 24.2, T121  
 Preclinical . . . . . 54, M220, W257  
 Prediction . . . . . 5.2, 24.4, 57, M21, T80  
 Prediction Error . . . . . T42  
 Predictive Model . . . . . 5.1, M21, M133  
 Predictors of Response. . . . . M97, T87  
 Prefrontal Circuit. . . . . T196  
 Prefrontal Cortex. . . . . 3.1, 6, 14.3, 17.1, 29.4, 37.3, 59.3, M65,  
 M105, M142, M275, T44, T236, W43,  
 W171, W184, W262  
 Prefrontal-Amygdala-Connectivity . . . . . M43, T12  
 Pregnancy . . . . . 1.1  
 Prelimbic . . . . . T51, T52  
 Prematurity. . . . . M155, T17  
 Premenstrual Dysphoric Disorder. . . . . M74, T131, W72  
 Pre-Morbid IQ . . . . . M168  
 Prenatal . . . . . 22.1, 22.2  
 Prenatal SSRI Exposure . . . . . M122, W52  
 Prenatal Stress. . . . . 22.3, M138, W34, W158  
 Prepulse Inhibition . . . . . T35, T215, W18, W206, W211  
 Prescription Drug Abuse . . . . . W252  
 Prescription Opioids . . . . . 35.4, W275  
 Presynaptic Uptake . . . . . W223  
 Preterm. . . . . M155  
 Prevention. . . . . 51  
 Prevention of Alzheimer's Disease . . . . . M51, M52  
 Primate Model. . . . . W41  
 Probiotics . . . . . W125  
 Prodrug. . . . . W252  
 Progesterone . . . . . W98  
 Prolactin . . . . . M149  
 Prophylactic . . . . . W92, W135  
 Prostaglandin . . . . . 44.4  
 Prostaglandin-Endoperoxide Synthase 1 . . . . . M216  
 Protein Interactions. . . . . 43.2  
 Protein Trafficking . . . . . M196  
 Proteomics . . . . . M196, T31  
 Proton Magnetic Resonance Spectroscopy. . . . . M148, T47  
 PSD-95 . . . . . M185  
 P-Selectin . . . . . T46  
 Psilocybin . . . . . M274  
 Psychiatric Comorbidity. . . . . T74, W244  
 Psychiatric Cross Disorder Risk . . . . . W146  
 Psychiatric Disorders . . . . . 48, W92  
 Psychiatric Genetics. . . . . W117, W225

Psychological Autopsy . . . . .	M136	Reinforcement-Based Decision-Making . . . . .	T106
Psychometric Properties . . . . .	26	Reinstatement . . . . .	T231, W279
Psychoneuroimmunology . . . . .	M262, W31	Rejection . . . . .	W124
Psychopharmacology . . . . .	W218	Relapse . . . . .	14.4, M275, M281, T115
Psychophysiology . . . . .	T8, W94	Relapse and Hospitalization . . . . .	W204
Psychosis . . . . .	27, 27.2, 28.4, M163, M172, M180, M205, M226, T181, T191, T234, W173, W179, W182	Relapse and Treatment Outcome . . . . .	M259
Psychosocial Stress . . . . .	25.4, T61, W143	Relapse Prevention . . . . .	50, M238, W125
Psychosocial Treatment . . . . .	T58	Relatives . . . . .	M163
Psychosomatic Medicine . . . . .	M102	Relevance for Outcomes . . . . .	61.1, T199
Psychostimulant . . . . .	6.1, T18, T237, W252	REM Sleep . . . . .	W95
Psychotherapy . . . . .	51.3, M19	Remission . . . . .	11.3, W85
Psychotic Disorders . . . . .	T223, W146	Repetitive Behavior . . . . .	W160
Psychotropic Medications . . . . .	T204	Repetitive Transcranial Magnetic Stimulation (rTMS) . . . . .	M20, M75, M104, T95, T120, T147
PTEN . . . . .	T173	Replication . . . . .	23
Puberty . . . . .	48, 48.1, 48.2	Reproducibility . . . . .	23
Punishment . . . . .	W262	Research Domain Criteria (RDoc) . . . . .	T110, T157, W13, W17, W136
Pupillometry . . . . .	W174	Residency Training . . . . .	39
Purkinje Cell . . . . .	44.4	Residual Symptoms . . . . .	T115
Pyramidal Neuron . . . . .	19	Resilience . . . . .	6.1, W4, W115
Quantitative Electroencephalography (qEEG) . . . . .	M158, T16	Respiration . . . . .	T73
R(-)-Ketamine . . . . .	W129	Respiratory Depression . . . . .	25.2
R(-)-Norketamine . . . . .	W129	Response Inhibition . . . . .	11.3, 37.4
Radiotracer . . . . .	T239	Resting State . . . . .	M19, W260
Rage . . . . .	40.3	Resting State Brain Imaging . . . . .	M256, W28
Randomized . . . . .	M79	Resting State fMRI . . . . .	49.3, 61.3, M39, M49, M85, M243, T24, T163
Randomized Clinical Trial . . . . .	35.2, 41.4	Resting State Functional Connectivity . . . . .	6.3, 16.1, 17.4, 28, 28.3, 32.2, 33.4, 38.4, 48.1, 55.4, 59.4, 61, M20, M33, M41, M56, M78, M94, M106, M161, M182, M197, M278, T57, T132, T137, T179, T238, T242, W97, W150
Randomized Controlled Trial . . . . .	2.3, 44.1	Resting State Intrinsic Connectivity . . . . .	11.3, W190
Rapastinel . . . . .	M131, T79	Retina . . . . .	21.3, T45, T134, T235
Rapid Antidepressant . . . . .	M96	Retrograde Tracing . . . . .	55.1
Rapid Antidepressant Effects . . . . .	M121	Rett Syndrome . . . . .	M31, T173
Rat . . . . .	T268, T272, W29, W87, W257	Reuptake Inhibitor . . . . .	M30, T103
Rat Models . . . . .	M33, M249, T68	Reversal Learning . . . . .	T106, W16
Reactive Astrocyte . . . . .	W165	Reward . . . . .	38.2, 49.1, T10, T81, T101, T190, T240, T267, W98, W231, W241
Reactive Attachment Disorder . . . . .	M32	Reward and Aversion . . . . .	T49, T260, W251
Real-Time fMRI Neurofeedback . . . . .	W171	Reward Circuitry . . . . .	30.4, 40.2, M56, M60, M83, T158, T266, W114
Reappraisal Training . . . . .	W170	Reward Devaluation . . . . .	T51
Receptor Activator of Nuclear Factor- $\kappa$ B Ligand (RANKL) . . . . .	16.4	Reward Network . . . . .	T164
Receptor Occupancy . . . . .	M154	Reward Neural Circuitry . . . . .	29.3, 32.2, 33.3, 33.4, 48.2
Receptor Trafficking . . . . .	W233	Reward Prediction Error . . . . .	33.2, M58, W59
Reconsolidation Intervention . . . . .	4.1	Reward Processing . . . . .	24.3, T122, T192, T241
Recovery . . . . .	T150, W85	Reward Sensitivity . . . . .	W178
Refinement . . . . .	6.1		
Regions of Interest . . . . .	M257		
Regulatory . . . . .	W228		
Reinforcement . . . . .	T252		
Reinforcement Learning . . . . .	33.2, M57, W63		

Reward-Based Decision-Making . . . 12.2, 31.4, 33, 37.1, M57, W64, W154	Self-Administration . . . . M228, M249, T259, W246, W268
Rhesus . . . . .55.2, T205	Self-Other Processing. . . . . T21, W54
Rho Family GTPase. . . . . M131	Self-Perception . . . . . W226
RiboTag . . . . . T117, W134, W156	Self-Referential . . . . . W61
Risk . . . . . W14	Self-Regulation . . . . . M39, M227, T13, T100
Risk and Resilience . . . . . M126, W40, W123	Semantic Priming . . . . . T216
Risky Decision-Making . . . . . M231, W232	Sensitization . . . . . M246, M279, T237, T264
Rivastigmine . . . . . W49	Sensorimotor Gating . . . . . T215
RNA . . . . . M202	Sensory Gating . . . . . W192
RNA Binding Protein. . . . . 20.3	Sensory-Emotional-Memory. . . . . W61
RNA Sequencing (RNA-Seq) . . . . . 43, 43.2, 59.1, M164, M193, M229, T11, T61, T117, W72, W156, W198	Serine Racemase . . . . . W165, W175
Rs10514299 . . . . . T266	Serotonin . . . . . M30, M82, W43, W237
Rumination. . . . . W138	Serotonin 1A Receptor. . . . . W120, W166
Safety . . . . . W228, W269	Serotonin 5-HT <sub>2C</sub> Receptor. . . . . W67
Safety Context. . . . . 55	Serotonin Reuptake Inhibitors . . . . . T131
Saliency Network. . . . . M256, T15	Serotonin Transporter . . . . . M231, W120
Samidorphan. . . . . T214, W87	Sex Differences . . . . . 1, 1.2, 27.1, 44.2, 44.3, 44.4, 48.2, 48.3, M34, M45, M61, M105, M135, M228, M233, M258, M267, M280, T28, T54, T84, T111, T117, T161, T226, T247, T268, T274, W2, W23, W31, W34, W36, W58, W60, W153, W237, W275
SAPAP3 . . . . . W16	Sex Steroids. . . . . 22.1, 48.2, M53, M135, T22
Scanner Harmonization . . . . . 7.2	Sexual Dimorphism . . . . . 38.1, M63, T124
Schizophrenia . . . . . 1.4, 6.1, 7.4, 8, 13, 13.3, 16, 16.3, 19.2, 19.4, 24, 24.2, 36, 36.2, 36.3, 42, 42.2, 44, 44.1, 47, 47.1, 47.3, 47.4, 60.2, 60.3, 61.1, M89, M164, M166, M169, M173, M175, M178, M181, M182, M183, M185, M186, M187, M190, M191, M192, M193, M195, M196, M198, M202, M204, M206, M208, M210, M212, M213, M214, M215, M216, M217, M226, T34, T35, T36, T39, T41, T42, T44, T46, T179, T182, T183, T184, T185, T186, T189, T192, T195, T196, T200, T201, T202, T203, T206, T209, T211, T212, T214, T215, T216, T218, T219, T220, T221, T222, W70, W108, W112, W172, W176, W177, W178, W180, W181, W186, W187, W188, W190, W196, W197, W198, W199, W201, W203, W205, W206, W207, W209, W210, W211, W212, W213, W215, W218, W219, W220, W224	Short-Term Clinical Studies . . . . . M210
Schizophrenia Databases . . . . . W186	Short-Term Studies . . . . . M211
Schizophrenia Genetics . . . . . 21.2, T213	shRNA . . . . . W114
Schizophrenia Negative Symptoms . . . . . T187	Side Effects . . . . . T41
Schizophrenia Prodrome . . . . . 60.4, T208	Sigma-1 Receptor. . . . . M2
Schizophrenia Subtypes . . . . . M168, M188, T193	Signal Transduction. . . . . 43.2
Schizophrenia-Like Behavior . . . . . T43, W70	Sign-Tracking . . . . . W231
Schizotypal Personality Disorder. . . . . T179	Simultaneous PET-MR. . . . . W166
Schizotypy. . . . . T194, W210	Single-Cell. . . . . W158
Screening . . . . . W44	SK Calcium-Activated Potassium Channels . . . . . T20
Seizure . . . . . T160, W215	Skin Conductance Responses . . . . . T71
	Sleep. . . . . 3.4, 21, 40, 40.1, 40.2, 40.4, M156, T228
	Sleep Deprivation . . . . . T219, T226, W132
	Sleep Disturbance . . . . . T225, T227
	Sleep Spindles . . . . . 21.2, T16, W195
	SLOS . . . . . W51
	Slow Waves. . . . . T16, W195
	Slow-Wave Sleep . . . . . M44, W95
	Smartphone-Based App . . . . . M81, T232
	Smoking . . . . . T50
	Smoking Status . . . . . W209
	snoRNA, miRNA and piRNA. . . . . 10.4
	SNP . . . . . T215
	Social Anxiety . . . . . M35
	Social Anxiety Disorder . . . . . T4

Social Behavior . . . . .	9.3, M48, M89, M138, M228, T2, T10, W41, W155	Structure-Activity Relationships . . . . .	W230
Social Cognition . . . . .	M197, M218, T194, W54, W181, W210, W222	Subchronic Ketamine Model . . . . .	42.3
Social Competence . . . . .	48.4	Subcortical Shape Analysis . . . . .	T136
Social Cue Detection . . . . .	M173	Subgenual . . . . .	M109
Social Defeat Stress . . . . .	M71, M184, T139, W107	Subgenual Cingulate Cortex . . . . .	T151
Social Deficits . . . . .	M249	Subjective Cognitive Decline . . . . .	W48
Social Discrimination . . . . .	T15	Subphenotypes . . . . .	T202
Social Functioning . . . . .	T218	Substance Abuse . . . . .	28, 40, M223, W258, W259
Social Interaction . . . . .	M26, M35, M137, M153, W43	Substance Use . . . . .	28.1, 28.2
Social Play Behavior . . . . .	44.4	Substance Use Disorder . . . . .	M227, M251, T157, W239
Social Preference . . . . .	M173	Subthalamic Nucleus . . . . .	M64
Social Reward . . . . .	W38	Subtypes . . . . .	57.3, M243, W260
Social Skills Training . . . . .	T218	Suicidal Ideation . . . . .	2.2
Social Status . . . . .	W157	Suicidality . . . . .	T95, W93
Social Stimuli . . . . .	W174	Suicide . . . . .	2.1, 11.1, M85, M90, M97, M111, M187, T25, T130, T149, T208, W82, W88, W124
Social Stress . . . . .	M134	Suicide Behavior Severity . . . . .	M69
Sociality . . . . .	M162	Superior Colliculus . . . . .	W25
Solriamfetol . . . . .	M222	Susceptibility . . . . .	W115
Soluble Epoxide Hydrolase . . . . .	W90	Susceptibility Genes . . . . .	1
Somatostatin . . . . .	19.3, M23, M209	Sustained Attention . . . . .	3.2, M146, T217
Sonic Hedgehog Signaling . . . . .	W227	Sustained Threat of Shock . . . . .	55.4
Spatial Navigation . . . . .	W194	Switch . . . . .	W185
Spiking Neural Models/Rate Models . . . . .	3.2	Symptom Trajectory . . . . .	11.2
Splice Variants . . . . .	25.2	Symptom-Onset Treatment . . . . .	T131
SSRI . . . . .	M36, T82, W17, W24	Synapses . . . . .	8, M130, M164, M204, M213, M215, W175
Staging . . . . .	5, 5.1, 5.2	Synaptic Aberrations . . . . .	7.4, M185, W70, W207
STAI . . . . .	W97	Synaptic Plasticity . . . . .	9, 14, 16.2, 17.2, T53, T98, W99, W130, W175, W261
STAR*D . . . . .	W101	Synaptic Protein Imaging . . . . .	W91
Statistical Methods . . . . .	W89	Synaptic Pruning . . . . .	T36
Stem Cells . . . . .	45, W227	Synaptic Vesicle . . . . .	W223
Stimulant . . . . .	W252	Synchronized Transcranial Magnetic Stimulation (sTMS) . . . . .	T145
STN, W8		Synchrony . . . . .	47.1
Stopping . . . . .	M64	Synthetic Opioids . . . . .	W281
Stress . . . . .	48.1, M73, M130, M162, M275, T26, W92	Systematic Review . . . . .	W182
Stress Cascades . . . . .	W217	Systemic Inflammation . . . . .	M8, M125
Stress Induced Depressive Behavior . . . . .	M116	Systems Neurobiology . . . . .	T196
Stress Models . . . . .	T127	TAAR 1 . . . . .	W257
Stress Reactivity . . . . .	M80, W237	Tardive Dyskinesia . . . . .	M149, M183, T159, W152
Stress Resilience . . . . .	M116	Target Engagement . . . . .	M154
Stress Response . . . . .	M164	Task-Based Functional Connectivity . . . . .	M180
Stress-Induced Reinstatement . . . . .	T54	Tau . . . . .	T96, W48, W207
Striatal Cortical Circuits . . . . .	W28	TCF4 . . . . .	T173
Striatum . . . . .	M142, T31, T101, T107, T233, T256, W5, W133, W160, W241	Team Building . . . . .	34
Structural MRI . . . . .	7, 7.1, 11.1, 11.2, 18.1, M32, W1	Technology . . . . .	M226, T182
Structural Neuroimaging . . . . .	7.3, M43, T191, W6	Teenage Onset . . . . .	T204
Structure of Psychopathology . . . . .	6.4		



Telomere . . . . . 22.3, 46.3, T113  
 Temperament . . . . . M119  
 Test Retest . . . . . M180  
 Testosterone . . . . . 48.4  
 Thalamo-Cortical Interactions . . . . . 3, 3.4  
 Thalamus . . . . . 3.2, 3.3, W195  
 Thalamus - Reticular Nucleus. . . . . 3.4  
 THC . . . . . 41, T234, T236, T246  
 Therapeutic Trial. . . . . T156  
 Therapeutics . . . . . 25, T96  
 Theta . . . . . 19.3, M17  
 Theta Burst Transcranial Magnetic Stimulation. . . . . W53  
 Threat. . . . . 4.3, 29.3  
 Threat Context . . . . . 55, 55.2  
 Threat Faces . . . . . 24.3  
 Threat of Shock. . . . . T126  
 Thyroid Hormone . . . . . M13  
 Tianeptine. . . . . 43.1  
 Time Estimation . . . . . M276  
 Timing . . . . . T32, T34, W194  
 TMEM161B/MEF2C . . . . . T266  
 TMS Targeting . . . . . M6  
 TMS-EEG . . . . . M15, W197  
 TNF-Alpha . . . . . W82  
 Tobacco . . . . . T50  
 Tobacco Smoking . . . . . W209, W270  
 Tolcapone . . . . . M159, M192  
 Tolerance . . . . . M219  
 Toll-Like Receptors (TLRs) . . . . . T108  
 Top-Down Control . . . . . 19.4, M146, T93  
 Touchscreen . . . . . M146, T110, T272  
 Tract Tracing . . . . . 55  
 Tractography. . . . . 18.2, T154  
 Training . . . . . 19.3, 39, T199  
 Trajectory . . . . . 11  
 Trajectory Modeling . . . . . M21  
 Transcranial Direct Current Stimulation (TDCS). . . . . 36.2,  
 36.3, M59, T, W191  
 Transcranial Magnetic Stimulation (TMS). . . . . 17.4, 24.1,  
 50.3, M6, M49, M158, M182,  
 M223, T176  
 Transcription. . . . . T183, W158  
 Transcription Factors. . . . . W73  
 Transcriptome. . . . . M70, M244, T230, 279  
 Transcriptomics. . . . . M31  
 Transcutaneous Auricular Vagus Nerve Stimulation  
 (taVNS) . . . . . T73  
 Transdiagnostic . . . . . 5.2, 26, M133, M172, M223, W13  
 Transgenerational . . . . . W31

Transgenic Mice . . . . . 30.3, W108  
 Transgenic Models. . . . . 45.2  
 Transition . . . . . 5.2  
 Translational . . . . . 48  
 Translational Approaches to Drug Development . . . . . 56  
 Translational Biomarker Development . . . . . 56.3, T129, W100  
 Translational Imaging . . . . . 32  
 Translational Medicine. . . . . W199  
 Translational Models . . . . . T69, W227  
 Translational Neuroscience . . . . . 29, 39, M117, M127,  
 T50, W131  
 Translational Pharmacology . . . . . M91, W15  
 Translational Research . . . . . 41.2, 54, T13, W31  
 Translocator Protein (TSPO) . . . . . 58, 58.1, 58.2, 58.3,  
 58.4, M115, W105, W217  
 Trauma. . . . . M19, M73, T64  
 Trauma Exposure . . . . . T65, W22  
 Traumatic Brain Injury (TBI). . . . . 58.4, M159, T169  
 Treatment . . . . . 15, 18, 41.4, 51, W6, W182, W224  
 Treatment Access . . . . . 35  
 Treatment Adherence . . . . . T156  
 Treatment Outcome. . . . . 52.2  
 Treatment Outcome Prediction . . . . . 49.2, 57.1, W229  
 Treatment Resistance. . . . . M84, T128, W80  
 Treatment Resistant Depression . . . . . 10.2, M87, M95,  
 M97, M110, M121, T11,  
 T28, T75, W76, W100, W119  
 Treatment Response . . . . . 49.1, M57, M124  
 Treatment-Resistant Schizophrenia. . . . . 52.3  
 TrkB. . . . . M123  
 TSPO and [11C]PBR-28 PET . . . . . 54.2, W270  
 Two-Photon . . . . . 37.1, M248, T31, T44  
 Type-2 Diabetes. . . . . M1  
 Ubiquitination. . . . . 52, 52.3  
 Ultra High-Risk Youth. . . . . W222  
 Unaffected Relatives. . . . . M174  
 Vagus Nerve . . . . . T99  
 Valbenazine. . . . . M149, M183, T159, W152  
 Validation . . . . . 31.3  
 Valproic Acid . . . . . T92  
 Varenicline . . . . . M260, M280, W209  
 Vascular Endothelial Growth Factor . . . . . T140  
 Vasopressin. . . . . 22.2, W41  
 Vasopressin 1A Receptor Antagonist . . . . . W42  
 VC/VS . . . . . W8  
 Venlafaxine . . . . . M99  
 Ventral Hippocampus . . . . . W11  
 Ventral Pallidum . . . . . M271, T261  
 Ventral Striatum . . . . . 49.1, M234, T244, W123, W248

Ventral Tegmental Area (VTA) . . . . .	30.1, M246, M269, T158, T252, T257, T267, W64, W273	White Matter Integrity. . . . .	W4, W202
Ventrolateral Prefrontal Cortex. . . . .	T150, W205	Whole Exome Sequencing . . . . .	T76
Ventromedial Prefrontal Cortex . . . . .	48.4, W272	Whole Genome Sequencing . . . . .	26
Verbal Memory . . . . .	M215	Whole-Cell Patch Clamp Recording . . . . .	W277
Vesicular Glutamate Transporter (VGLUT) . . .	W68, W223	Williams Syndrome . . . . .	M41
Veterans . . . . .	M118, W153	Wistar Kyoto Rat. . . . .	M153, W119
Virtual Reality. . . . .	4.4, M248	Withdrawal . . . . .	20
Visceral Obesity. . . . .	M53	Within Person Variance. . . . .	M175
Visual Information Processing . . . . .	19.3, M215, T104, T220	Women. . . . .	32.3, M1
Visual Perception . . . . .	T188	Women's Mental Health . . . . .	T56, T88, W22
Visual Plasticity. . . . .	60.2, 60.3	Working Memory . . . . .	3.1, 19.1, 31, 31.2, 36.2, 36.3, M6, M209, T59, T236, T268, W194, W202, W205
Visuospatial Ability . . . . .	M41	Working Memory fMRI. . . . .	61.3, M184, W138
Visuospatial Working Memory. . . . .	M204	xCT . . . . .	W254
VMAT2 . . . . .	T224, W152	Young Adults . . . . .	M78
Voxel-Based Morphometry (VBM). . . . .	M63, M156	Youth . . . . .	M200
Vulnerability . . . . .	W232, W263	Zebrafish. . . . .	T35, T90
Waitlist. . . . .	35.3	Zonulin. . . . .	M178
Weight Loss Treatment . . . . .	M60	$\beta$ -arrestin . . . . .	W193
White Matter. . . . .	11.3, 32.1, M155, W14, W187		
White Matter Fractional Anisotropy. . . . .	M179		